[BSTC] BioSpecifics Technologies Corp

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 54.66 Change: 2.27 (4.33%)
Ext. hours: Change: 0 (0%)

chart BSTC

Refresh chart

Strongest Trends Summary For BSTC

BSTC is in the medium-term up 17% above S&P in 3 months and up 60% above S&P in 1 year. In the long-term up 69% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren?s contracture and Peyronie?s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS1.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 111.07% Sales Growth - Q/Q20.56% P/E29.54
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA17.95% ROE18.48% ROI
Current Ratio31.82 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin55.74% Net Profit Margin36.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.08 M Cash From Investing Activities-2.15 M Cash From Operating Activities1.99 M Gross Profit
Net Profit2.33 M Operating Profit3.56 M Total Assets34.67 M Total Current Assets28.99 M
Total Current Liabilities910 K Total Debt Total Liabilities1000 K Total Revenue5.61 M
Technical Data
High 52 week71.62 Low 52 week38.52 Last close69.31 Last change-2.34%
RSI53.29 Average true range2.53 Beta0.4 Volume22.66 K
Simple moving average 20 days2.26% Simple moving average 50 days8.51% Simple moving average 200 days26.18%
Performance Data
Performance Week-3.23% Performance Month8.33% Performance Quart23.28% Performance Half31.29%
Performance Year79.42% Performance Year-to-date14.37% Volatility daily1.93% Volatility weekly4.31%
Volatility monthly8.83% Volatility yearly30.57% Relative Volume155.17% Average Volume42.39 K
New High3.64% New Low

News

2019-03-20 09:00:01 | BioSpecifics BSTC Upgraded to Strong Buy: Here's What You Should Know

2019-03-18 08:01:00 | BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman

2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-02-21 11:27:06 | Is BioSpecifics Technologies Corp. NASDAQ:BSTC A Volatile Stock?

2019-02-04 07:35:00 | Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-28 09:32:02 | BioSpecifics BSTC Upgraded to Buy: Here's What You Should Know

2019-01-17 09:30:02 | Is BioSpecifics Technologies BSTC Stock Outpacing Its Medical Peers This Year?

2019-01-16 10:36:37 | Is BioSpecifics Technologies Corp.’s NASDAQ:BSTC Balance Sheet Strong Enough To Weather A Storm?

2019-01-11 10:32:03 | Ocular OCUL Submits an sNDA for Eye Pain Drug Dextenza

2019-01-10 11:00:04 | INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

2019-01-10 08:43:01 | Weakness Seen in Champions Oncology CSBR Estimates: Should You Stay Away?

2019-01-09 09:45:02 | Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

2019-01-03 10:29:03 | Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study

2019-01-03 10:26:03 | Flexion Starts Phase III Enrollment on Zilretta for Hip OA

2019-01-02 09:25:02 | Portola Up as Large-Scale Andexxa Production Gets FDA Nod

2018-12-28 09:45:02 | Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis

2018-12-25 09:30:02 | Is BioSpecifics Technologies BSTC Outperforming Other Medical Stocks This Year?

2018-12-19 15:09:08 | Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

2018-12-17 10:29:12 | Here’s What BioSpecifics Technologies Corp.’s NASDAQ:BSTC P/E Is Telling Us

2018-12-12 10:15:03 | Portola PTLA Down as CHMP Defers Review Date for Ondexxya

2018-12-11 17:44:10 | Jazz JAZZ Increases Share Buyback Authorization by $400M

2018-12-11 09:22:02 | Novan Announces Top-Line Data From Mid-Stage Molluscum Study

2018-12-11 08:40:01 | Why Tilray TLRY Could Be Positioned for a Slump

2018-12-06 08:46:01 | Should You Get Rid of Aerie Pharmaceuticals AERI Now?

2018-11-29 16:47:09 | Theravance Pipeline Strong, Plans Yupelri Launch by Year End

2018-11-28 10:20:03 | Theravance's Respiratory Disease JAK Inhibitor Enters Phase I

2018-11-28 08:15:00 | Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings

2018-11-27 13:26:21 | Is BioSpecifics Technologies Corp. NASDAQ:BSTC Worthy of Your Portfolio?

2018-11-21 11:15:04 | Theravance JAK Inhibitor Enters Phase II for Crohn's Disease

2018-11-21 09:58:02 | IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance

2018-11-20 16:25:39 | IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses

2018-11-20 08:45:01 | Galmed Pharmaceuticals GLMD in Focus: Stock Moves 6.2% Higher

2018-11-20 08:33:01 | TESARO TSRO Jumps: Stock Rises 5.4%

2018-11-15 16:30:00 | BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development

2018-11-15 14:15:15 | Managers Of This Fund Like The Outlook For Small-Cap Stocks

2018-11-15 12:35:22 | Is BioSpecifics Technologies Corp NASDAQ:BSTC Excessively Paying Its CEO?

2018-11-09 09:20:02 | BioSpecifics Technologies BSTC Q3 Earnings and Revenues Beat Estimates

2018-11-09 08:13:25 | BioSpecifics: 3Q Earnings Snapshot

2018-11-09 08:01:00 | BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results

2018-11-06 10:31:03 | What's in the Cards for BioSpecifics BSTC in Q3 Earnings?

2018-11-02 10:30:02 | BioSpecifics Technologies BSTC Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2018-10-31 16:30:00 | BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids

2018-10-25 14:27:24 | IBD Stock Of The Day Outperforms Biotech Sector In A Rough October

2018-10-19 08:45:00 | Investor Expectations to Drive Momentum within Ultrapar Participacoes S.A, BioSpecifics Technologies, GSV Capital, 58, Mitel Networks, and Amarin — Discovering Underlying Factors of Influence

2018-10-09 10:01:02 | Affimed Down After Clinical Hold on Two Early-Stage Studies

2018-10-08 09:44:01 | Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings

2018-10-05 08:56:12 | BioLineRx BLRX in Focus: Stock Moves 7.5% Higher

2018-10-05 08:40:12 | Champions Oncology CSBR Soars: Stock Adds 10.7% in Session

2018-10-05 07:48:11 | 4 Stocks With Recent Price Strength to Maximize Your Gains